Ontology highlight
ABSTRACT:
INSTRUMENT(S): Orbitrap Fusion, Q Exactive
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Melanocyte, Skin
DISEASE(S): Melanoma
SUBMITTER: Manfredo Quadroni
LAB HEAD: Liliane Michalik
PROVIDER: PXD009108 | Pride | 2019-02-18
REPOSITORIES: Pride
Action | DRS | |||
---|---|---|---|---|
20160526_Pich_8462_140min_2ul.raw | Raw | |||
20160526_Pich_8463_140min_2ul.raw | Raw | |||
20160706_Pich_8541_140min_2ul.raw | Raw | |||
20160706_Pich_8542_140min_2ul.raw | Raw | |||
20160819_Pich_8609_140min_2ul.raw | Raw |
Items per page: 5 1 - 5 of 23 |
Pich Christine C Meylan Patrick P Mastelic-Gavillet Beatris B Nguyen Thanh Nhan TN Loyon Romain R Trang Bao Khanh BK Moser Hélène H Moret Catherine C Goepfert Christine C Hafner Jürg J Levesque Mitchell P MP Romero Pedro P Jandus Camilla C Michalik Liliane L
Cancer research 20180905 22
In addition to improving insulin sensitivity in type 2 diabetes, the thiazolidinedione family of compounds and the pharmacologic activation of their best-characterized target PPARγ have been proposed as a therapeutic option for cancer treatment. In this study, we reveal a new mode of action for the thiazolidinedione rosiglitazone that can contribute to tumorigenesis. Rosiglitazone activated a tumorigenic paracrine communication program in a subset of human melanoma cells that involves the secret ...[more]